DNA RNA and Cells

14 Feb 2018 Poseida Therapeutics Presents Stem Cell Memory CAR-T Therapy for Prostate Cancer at 2018 Keystone Symposia on Emerging Cellular Therapies
13 Feb 2018 Obsidian Therapeutics Presents Data Demonstrating Regulation of Protein Activity with its Next-Generation CAR-T Platform at Keystone Symposium on Emerging Cellular Therapies
13 Feb 2018 Synlogic Presents Data from Immuno-Oncology Development Program Demonstrating Potent Anti-Tumor Immunity Following Administration of Novel STING Agonist-producing Synthetic Biotic™ Medicine
13 Feb 2018 Nantkwest and Frankfurt University Hospital Announce First in Human Dosing of off-the-Shelf HER2.taNK (Car–natural Killer) Cell Therapy in Glioblastoma
13 Feb 2018 Smart bomb virus shows promise as brain tumor immunotherapy
13 Feb 2018 Audentes Therapeutics Announces Dosing of First Patient in VALENS, a Phase 1/2 Clinical Trial of AT342 for the treatment of Crigler-Najjar Syndrome
12 Feb 2018 Ziopharm Oncology Presents Data on Very Rapid Production of CAR T Cells at Keystone Symposia Emerging Cellular Therapies: T Cells and Beyond
09 Feb 2018 REGENXBIO Announces Completion of Dosing of Third Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD
08 Feb 2018 Herantis Pharma completes patient enrolment in Phase 1 study of Lymfactin gene therapy for secondary lymphedema and has submitted Phase 2 application
07 Feb 2018 Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial
07 Feb 2018 Akcea Completes Enrollment in Phase 2b Study of AKCEA-APO(a)-LRx
07 Feb 2018 Audentes Therapeutics Announces Selection of Optimized Clinical Development Candidate for Pompe Disease Program
07 Feb 2018 Sangamo Therapeutics Presents Initial Safety Data from CHAMPIONS Genome Editing Study for MPS II at WORLDSymposium
06 Feb 2018 Fibrocell Announces Submission of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma
04 Feb 2018 miRagen Therapeutics Presents New Data from Phase 1 Clinical Trial of MRG-106 in Mycosis Fungoides at the T-Cell Lymphoma Forum
02 Feb 2018 Alnylam Announces FDA Acceptance of New Drug Application (NDA) and Priority Review Status for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
01 Feb 2018 Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL
31 Jan 2018 Bellicum Pharmaceuticals Announces Clinical Hold on BPX-501 Clinical Trials in the United States
29 Jan 2018 SillaJen Announces First Patient Enrolled in the NCI-Sponsored Trial Evaluating Combination Therapy in Colorectal Cancer with SillaJen's Pexa-Vec Oncolytic Immunotherapy
26 Jan 2018 Alnylam Announces EMA Acceptance of Marketing Authorisation Application (MAA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
25 Jan 2018 Rexgenero Treats First Patient in its Phase III Programme with Lead Product REX-001, a Novel Cell Therapy for the Treatment of Critical Limb Ischemia (CLI)
25 Jan 2018 American Gene Technologies Announces Progress toward Phase I Clinical Trial of AGT103-T for HIV Functional Cure
25 Jan 2018 Iovance Biotherapeutics Announces Preliminary Phase 2 Data for TIL Treatment in Head and Neck and Cervical Cancers
24 Jan 2018 Voyager Therapeutics Announces FDA Clearance of Investigational New Drug Application for VY-AADC for Advanced Parkinson’s Disease
23 Jan 2018 AnGes Submits Application for Marketing Approval to PMDA for HGF gene therapy for Critical Limb Ischemia

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up